222
to22s Bio-Systems Systems Biology • Natural Chemistry
Computational Biophysics • Heritage Seedline Discovery

Deciphering Nature’s
Forgotten Chemotypes.

to22s Bio-Systems combines explicit-solvent molecular dynamics with rare triterpenoid scaffolds derived from domestic purple rice genetics (Oryza sativa L.)—exploring non-canonical allosteric mechanisms in oncology and cellular membrane resilience.

// PHYSICAL SEEDLINE
USDA-Tiara
Heritage Purple Rice Stock
// IN SILICO ENGINE
OpenMM
Explicit-Solvent Dynamics
// ONCOLOGY THESIS
Bcl-2 Allostery
Non-Groove Resistance Sites
// RESEARCH PIPELINE
SBIR / STTR
Federal Phase I Dockets
// The In Silico Edge

Evolutionary Scaffolds.
Atomic Precision.

Natural products evolved over millions of years to interact selectively with biological systems. We pair these privileged chemical architectures with modern physics-based modeling to discover new therapeutic possibilities.

// MOLECULAR DIVERSITY

Privileged Triterpenes

The cycloartane core from rice bran features a rigid 9,19-cyclopropane ring, unlocking conformational spaces and stereochemical diversity that synthetic medicinal chemistry libraries rarely sample.

// COMPUTATIONAL RIGOR

Explicit-Solvent MD

We move past static docking grids into fully solvated, dynamic conformational ensembles—translating atomic simulations into concrete, actionable hypotheses for targeted wet-lab validation.

// ALLOBINDING SITES

Beyond Orthosteric Grooves

By investigating alternative, non-canonical allosteric pockets, we explore whether natural triterpenoid scaffolds can modulate protein function when standard drug binding pockets acquire resistance mutations.

// Research Theses

Active Federal Programs

Two targeted grant proposals filed in September 2026, pairing our in silico screening with accredited university core facilities and specialized contract research organizations.

National Cancer Institute • SBIR Phase I

Bcl-2 Allostery & Resistance Dynamics

Targeted oncology therapies like venetoclax frequently encounter acquired resistance through mutations in the BH3 groove (such as G101V). Our computational campaign investigates whether rare rice-derived diol scaffolds can engage alternative back-face surfaces on Bcl-2 to bypass groove-specific resistance.

// Validation Architecture:
  • Planned SPR kinetic binding screens at Reaction Biology
  • Analytical LC-MS release kinetics at USF CPAS core
  • Focus: Chronic lymphocytic leukemia (CLL) models
Review Track: NCI SBIR Peer Review
NIH / NIAID STTR Phase I • NDI Pipeline

ORYZA-NDI-1 • Lipid Architecture

Advancing a defined, standardized phytosterol microparticle formulation from domestic rice bran. Focused on physicochemical stability, particle sizing, and host cellular safety profiling toward an eventual New Dietary Ingredient (NDI) regulatory framework.

// Validation Architecture:
  • University of South Florida College of Public Health partnership
  • Dynamic Light Scattering (DLS) & zeta-potential characterization
  • Rigorous preclinical safety & toxicology battery
Review Track: NIH STTR Peer Review
// Agricultural Ground

From Heritage Grain
To Atomic Targets.

Before a molecule can become a therapeutic lead, it needs an authentic physical origin. Rather than relying on petroleum-derived starting blocks, our discovery pipeline is anchored in the natural metabolic machinery of domestic rice bran.

In 2026, to22s Bio-Systems secured 100 pounds of foundation seed of the USDA-Tiara purple rice lineage, transferred from the USDA Agricultural Research Service (Dale Bumpers National Rice Research Center in Stuttgart, Arkansas). Tiara is a high-yield genetic outlier renowned for deep anthocyanin pigmentation and enriched triterpene profiles.

100 lbs Seed
Foundation stock received from USDA-ARS.
Upcycled Feedstock
Utilizing nutrient-dense domestic milling bran.
Natural Scaffolds
Direct source of rare cycloartane sterols.

USDA-Tiara Lineage Spec

Oryza sativa L. • ARS Germplasm
Germplasm Origin: Stuttgart, Arkansas (USDA-ARS)
Grain Morphology: High-Anthocyanin Purple Pericarp
Target Metabolite Pool: Cycloartenol, Cycloartanol, γ-Oryzanol
Processing Strategy: Supercritical CO2 & Enzymatic Cleavage
Renewable Agricultural Feedstock • Zero Petroleum Solvents • Sustainable Bioeconomy
// Milestones

R&D Execution Roadmap

A disciplined, milestone-driven pathway transitioning from computational biophysics to wet-lab experimental validation.

// PHASE 01 ACTIVE

In Silico & Genetic Foundation

  • Explicit-solvent MD conformational modeling
  • 100 lbs USDA-Tiara foundation seed secured
  • Federal SBIR / STTR Phase I submissions
  • Collaborative SOW alignment with USF & CROs
// PHASE 02 UPCOMING

Biophysical & Core Validation

  • Surface Plasmon Resonance (SPR) binding kinetics
  • High-resolution LC-MS/Q-ToF release profiles
  • Initial cell viability & apoptosis readouts
  • Peer-review award execution upon study section
// PHASE 03 EXPANSION

Scale-Up & Delivery Matrices

  • Supercritical CO2 pilot toll-fractionation
  • Self-assembling natural lipid carrier optimization
  • NDI regulatory dossier compilation
  • Preclinical in vivo safety & PK/PD profiling
// Research Network

Collaborative Ecosystem

Capital-efficient execution pairing in-house computational discovery with accredited research partners.

// APPLICANT SBC

to22s Bio-Systems, Inc.

Safety Harbor, FL

Lead computational modeling (OpenMM), allosteric hypothesis generation, feedstock supply chain coordination, and grant project leadership.

// SUBCONTRACTED CRO

Reaction Biology

Malvern, PA • Accredited US Facility

Surface Plasmon Resonance (SPR) biophysical kinetics, cell-based viability assays, Caspase 3/7 apoptosis screens, and early safety profiling.

// UNIVERSITY CORE FACILITIES

University Core Infrastructure

USF CPAS, LAMSAT & Public Health

Dynamic Light Scattering (DLS) particle sizing, high-resolution LC-MS/Q-ToF analytical release kinetics, and regulatory toxicology design.

// Connect

Let’s Build Together.

Whether you are a grant study section reviewer, academic researcher in natural product biophysics, or biopharma collaborator—we welcome dialogue.